Ac­cel­er­at­ed ap­proval will be 'the nor­m' for gene ther­a­pies, FDA's Pe­ter Marks says

The FDA will in­creas­ing­ly use ac­cel­er­at­ed ap­proval for gene ther­a­pies aimed at rare con­di­tions, ac­cord­ing to Pe­ter Marks, the FDA’s top of­fi­cial over­see­ing cell and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER